Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > HIV-2

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Mar 13, 2022 1:38pm

109 Views

Post# 34510131

RE:HIV-2

Scarlet,
Should we expect to see a marketing push soon from Paul for this? guessing this revision could possibly be the start of that effort.

scarlet1967 wrote:

They have published the revised study (March 8) re the efficacy of Trogarzo for HIV2 and Christian is one of the co authors.

https://pubmed.ncbi.nlm.nih.gov/35262531/?utm_source=gquery

The original PR below:

“Based on results obtained in vitro, it is expected that ibalizumab could have some efficacy in patients infected with HIV-2. HIV-2 multidrug resistance is on the rise in Europe and West Africa and there are limited therapeutic options, if any. The results obtained by the team of researchers in Paris are good news to patients with HIV-2 as ibalizumab could become an add-on to an optimized background regimen for people with an uncontrolled HIV-2,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.

Theratechnologies Announces Ibalizumab Inhibits HIV-2 In